Background To evaluate the diagnostic accuracy of the WHOeyes smartphone application for screening distance and near visual ...

Background/Aims To investigate the characteristics of fast-progressors among Asian patients with normal tension glaucoma (NTG) and identify the risk factors associated with fast progression of ...

Purpose To determine the independent and joint effects of nighttime light exposure and sleep duration on childhood myopia and ...

Development and validation of a deep learning model for automatic assessment of corneal endothelium ...

Background/aims To compare long-term outcomes of the Ahmed Glaucoma Valve (AGV) and PAUL Glaucoma Implant (PGI) over a minimum of 3 years. Methods This retrospective comparative study included 146 ...

Background To assess whether adjunctive topical voriconazole 1% offers additional benefit over natamycin 5% monotherapy in fungal keratitis, focusing on ulcer resolution, visual outcomes and safety.

Resident Ophthalmology, Department of Ophthalmology, University Medical Center Utrecht, The Netherlands Correspondence to Robert P L Wisse, Department of Ophthalmology, University Medical Center, ...

Aims To compare 1-year and 2-year outcomes of eyes with persistent and non-persistent diabetic macular oedema (DME) treated with vascular endothelial growth factor (VEGF) inhibitors. Methods This was ...

2 Nimagadda Prasad Children's Eye Care Centre, L V Prasad Eye Institute, Visakapatnam, India Correspondence to Dr Ramesh Kekunnaya, Head, Jasti V Ramanamma Children's Eye Care Centre, Paediatric ...

Background/aims Fenofibrates may slow progression of diabetic retinopathy (DR). This study used the large international TriNetX database to evaluate progression of retinopathy and development of ...

Correspondence to Dr Yoshio Hirano, Department of Ophthalmology & Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya 4678601, Japan; yoshio.hirano{at}gmail.com Aims To ...

The study by Lakhani et al 1 scrutinises data from the US Food and Drug Administration (FDA) Adverse Event Reporting System, revealing formulation and sex-specific associations of the anti-obesity ...